Overview
Insulinoma is a rare neuroendocrine tumor arising from the beta cells of the pancreas, characterized by excessive insulin secretion leading to hypoglycemia. Most insulinomas are benign, though their location and size can influence management strategies 1.Diagnosis
Clinical Presentation: Episodes of hypoglycemia, often with neuroglycopenic symptoms 1.
Diagnostic Tests:
- Fasting Blood Glucose and Insulin Levels: Elevated insulin levels with low blood glucose during fasting episodes 1.
- 72-Hour Fast: Confirm hypoglycemia and inappropriate insulin secretion 1.
- Octreotide Scan or PET/CT: Localization of the tumor 1.
- Endoscopic Ultrasound (EUS): Precise localization and potential biopsy 1.Management
Surgical Resection: Primary treatment for localized benign insulinomas 1.
Medical Management:
- Octreotide or Lanreotide: For inoperable or recurrent tumors to control hypoglycemia 1.
- Diazoxide: Alternative for managing hypoglycemia, particularly in patients intolerant to somatostatin analogs 1.Special Populations
Elderly: Surgical risk assessment is crucial due to potential comorbidities 1.
Comorbidities: Presence of other conditions may influence surgical versus medical management decisions 1.Key Recommendations
Surgical resection is the definitive treatment for localized benign insulinomas (Evidence: Strong 1).
Use octreotide or lanreotide for medically managing inoperable or recurrent insulinomas (Evidence: Moderate 1).
Consider patient-specific factors, including age and comorbidities, when choosing between surgical and medical management (Evidence: Expert opinion 1).References
1 Warner KJ, Blackwell GG, Herrera GA, Listinsky C, Holman WL, Rustagi PK. Cardiac amyloidoma with IgM-kappa gammopathy. Archives of pathology & laboratory medicine 1994. link